Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer

RCT of 2526 patients, found that addition of celecoxib to standard adjuvant fluorouracil, leucovorin, and oxaliplatin did not significantly improve disease-free survival vs placebo (76.3% vs 73.4% at 3 years; HR, 0.89; 95% CI, 0.76-1.03; P = 0.12).

Source:

Journal of the American Medical Association